2.19
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss By Investing.com - Investing.com Nigeria
Earnings call transcript: Aytu BioPharma Q3 2026 reveals earnings miss - Investing.com
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - ACCESS Newswire
Pharma firm Aytu BioPharma to present at virtual investor event May 28 - Stock Titan
Aytu outlines $6M-$7M quarterly sales and marketing spend range as EXXUA scripts rise to over 920 in April - MSN
Aytu BioPharma to Participate in September 2022 Investor Conferences - The Chronicle-Journal
Aytu BioPharma, Inc.Common Stock (NQ: AYTU - The Chronicle-Journal
What Aytu Bio AYTU is doing that separates it from the herd Institutional Selling 20260507Expert Trade Signals - Newser
Analysts Expect Breakeven For Aytu BioPharma, Inc. (NASDAQ:AYTU) Before Long - Sahm
AYTU Stock Price, Quote & Chart | AYTU BIOPHARMA INC (NASDAQ:AYTU) - ChartMill
AYTU BIOPHARMA INC | BIG RISK REWARD | AYTU STOCK | AYTU BIOPHARMA STOCK (K8VNph4cYO) - fathomjournal.org
Aytu BioPharma, Inc. Q3 2026 Earnings Call Summary - Yahoo Finance
Aytu BioPharma Inc (AYTU) Q3 2026 Earnings Call Highlights: Stro - GuruFocus
Is Aytu BioPharma (AYTU) Overvalued After Q3 FY2026 Earnings Mis - GuruFocus
Aytu (AYTU) Reports Strong Q3 Revenue and Positive Launch Moment - GuruFocus
Aytu BioPharma, Inc. (AYTU) reports Q3 loss, tops revenue estimates - MSN
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates - sharewise.com
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu (AYTU) Q3 2026 Earnings Transcript - The Globe and Mail
Full Transcript: Aytu BioPharma Q3 2026 Earnings Call - Yahoo Finance
Aytu BioPharma (NASDAQ:AYTU) Surges 23% as EXXUA Launch Gains Early Traction in Mixed Q3 Results - ChartMill
AYTU BIOPHARMA Q3 EPS USD -0.53 - Moomoo
Aytu BioPharma (AYTU) swings to loss while launching EXXUA and cutting warrant liabilities - Stock Titan
EXXUA launch reshapes Aytu BioPharma (Nasdaq: AYTU) Q3 2026 results - Stock Titan
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results - ChartMill
MSN Money - MSN
Aytu BioPharma Q3 Earnings Announcement Scheduled - Intellectia AI
Aytu Biopharma Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
AYTU: Aytu BioPharma, Inc.Interactive Chart - Zacks Investment Research
What Aytu Bio (AYTU) is doing that separates it from the herd (Institutional Selling) 2026-05-07AI Powered Stock Picks - newser.com
Number of shareholders of Aytu BioPharma, Inc. – LS:A3D38R - TradingView
Aytu BioPharma sets May 13 Q3 2026 results call after close - Stock Titan
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026 - ACCESS Newswire
Favourable Signals For Aytu BioPharma: Numerous Insiders Acquired Stock - Yahoo Finance
Aytu BioPharma, Inc. (AYTU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
EPS Watch: Is Aytu BioPharma Inc forming a double bottom2026 Stock Rankings & Reliable Entry Point Trade Alerts - baoquankhu1.vn
AYTU Stock Analysis: Aytu BioPharma Inc. biotech stock at 2.68 posts 1.52 percent daily gain - Cổng thông tin điện tử tỉnh Lào Cai
Aytu BioPharma amends warrants to address accounting classification - Investing.com
Aytu BioPharma amends warrants to address accounting classification By Investing.com - Investing.com Canada
Aytu BioPharma Amends Investor Warrants to Restore Equity Classification and Reduce Liabilities - TradingView — Track All Markets
Aytu BioPharma (NASDAQ: AYTU) rewrites warrant terms to restore equity - Stock Titan
Aytu BioPharma Inc (AY20.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
AYTU PE Ratio & Valuation, Is AYTU Overvalued - Intellectia AI
What analysts say about Aytu BioPharma Inc stock2026 Support & Resistance & Weekly Top Stock Performers List - baoquankhu1.vn
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):